Sintilimab Combined With GEMOX ± IBI305 (Bevacizumab Biosimilar) Versus GEMOX in Advanced Intrahepatic Cholangiocarcinoma
Status:
Recruiting
Trial end date:
2025-01-13
Target enrollment:
Participant gender:
Summary
A randomized controlled, phase II clinical trial is designed to compare the safety and
efficacy of Sintilimab combined with GEMOX ± IBI305 and GEMOX as first-line therapy in
advanced intrahepatic cholangiocarcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital